819 reports of this reaction
2.0% of all FELODIPINE EXTENDED RELEASE TABLETS reports
#6 most reported adverse reaction
HEADACHE is the #6 most commonly reported adverse reaction for FELODIPINE EXTENDED RELEASE TABLETS, manufactured by Aurobindo Pharma Limited. There are 819 FDA adverse event reports linking FELODIPINE EXTENDED RELEASE TABLETS to HEADACHE. This represents approximately 2.0% of all 41,995 adverse event reports for this drug.
Patients taking FELODIPINE EXTENDED RELEASE TABLETS who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for FELODIPINE EXTENDED RELEASE TABLETS, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for FELODIPINE EXTENDED RELEASE TABLETS:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 819 FDA reports for FELODIPINE EXTENDED RELEASE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.0% of all adverse event reports for FELODIPINE EXTENDED RELEASE TABLETS, making it a notable side effect.
If you experience headache while taking FELODIPINE EXTENDED RELEASE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.